Skip to main content

Flagship Pioneering — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

70
Companies
$4.9B
Total invested
$73.8M
Avg. check
16
Industries
Biotechnology 20Therapeutics 11Health Care 10Medical 10Life Science 5Artificial Intelligence (AI) 4+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 70
Tarveda Therapeutics
September 2021

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors.

Biotechnology · Watertown$6.0M Venture - Series Unknown
Mirai Bio
September 2024

Mirai Bio provides access to end-to-end development capabilities with innovation at every step.

Artificial Intelligence (AI) · Cambridge$50.0M Series A
Extuitive
September 2025

Extuitive is an AI-first business that aims to revolutionize the conception and validation of new consumer goods and creatives.

Artificial Intelligence (AI) · Cambridge$20.0M Seed
Codiak Biosciences
September 2022

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.

Biotechnology · San Francisco$20.0M Post-IPO Equity
Laronde
August 2021

Laronde develops an eRNA-based therapeutic platform that is capable of indicating diverse proteins inside the body.

Biotechnology · Cambridge$440.0M Series B
Senda Biosciences
August 2022

Senda Biosciences is a therapeutics platform company leveraging unprecedented insights into the molecular connections between humans.

Biotechnology · Cambridge$123.0M Series C
Apriori Bio
July 2024

Apriori Bio offers a platform for creating variant-resilient vaccines and provides real-time insights to prepare for future outbreaks.

Biotechnology · Boston$1.1M Grant
Evelo Biosciences
July 2023

Evelo Biosciences is a biotechnology company that develops oral biologics for small intestinal axis with systemic therapeutic effects.

Biotechnology · Cambridge$25.5M Post-IPO Equity
Empress Therapeutics
June 2023

Empress Therapeutics is to generate transformative drug candidates that get to the clinic faster and cheaper.

Artificial Intelligence (AI) · Cambridge$50.0M Venture - Series Unknown
Prologue Medicines
May 2024

Prologue Medicines creates transformative medicines by systematically discovering and evaluating viral proteins and their unique features.

Health Care · Cambridge$50.0M Series A
ProFound Therapeutics
May 2022

ProFound Therapeutics is creating profound impacts on the understanding of biology and disease and the ability to create therapeutics.

Biotechnology · Cambridge$75.0M Series A
Metaphore Biotechnologies
April 2026

Metaphore Biotechnologies is a firm that uses biomimicry and machine learning to unlock the revolutionary therapeutic.

Biotechnology · CambridgeVenture - Series Unknown
Serif Bio­med­i­cines
April 2026

Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology.

Cambridge$50.0M Venture - Series Unknown
Ring Therapeutics
March 2023

Ring Therapeutics is a gene therapy company focused on discovering and developing programmable genetic medicines.

Biotechnology · Cambridge$86.5M Series C
Vesalius Therapeutics
March 2022

Vesalius Therapeutics is focused on redefining the understanding and treatment of the diseases that drive ninety percent of human illness.

Biotechnology · Cambridge$75.0M Series A
Omega Therapeutics
February 2023

Omega Therapeutics offers a proprietary epigenomic programming platform.

Biotechnology · Cambridge$40.0M Post-IPO Equity
Terrana Biosciences
July 2025

Terrana's innovative technology platform uses RNA-based plant health solutions to enable resilient agriculture for a world.

Agriculture · Cambridge$50.0M Series B
Etiome
April 2025

Etiome, a company redefining how we detect and preempt disease progression.

Biotechnology · Cambridge$50.0M Series A
Ampersand Biomedicines
March 2025

Ampersand Biomedicines is a multi-product platform that develops programmable medicines that target disease sites precisely.

Biopharma · Boston$65.0M Series B
Lila Sciences
March 2025

Lila Sciences creates a scientific superintelligence platform and autonomous labs for life sciences, chemistry, and materials science.

Artificial Intelligence (AI) · Cambridge$200.0M Seed
Quotient Therapeutics
November 2023

Quotient Therapeutics engages in transformative medicines made possible with somatic genomics.

Biotechnology · London$50.0M Seed
Alltrna
August 2023

Alltrna is the creator of a tRNA platform that aims to decipher tRNA biology and pioneer therapies for disease treatment.

Biotechnology · Cambridge$109.0M Series B
Foghorn Therapeutics
January 2026

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,

Biopharma · Cambridge$50.0M Post-IPO Equity
Denali Therapeutics
December 2025

Denali Therapeutics is dedicated to defeating neurodegenerative diseases to deliver safe and effective medicines to patients and families.

Biotechnology · San Francisco$200.0M Post-IPO Debt

Where Flagship Pioneering invests

Biotechnology20
Therapeutics11
Health Care10
Medical10
Life Science5
Artificial Intelligence (AI)4

About Flagship Pioneering's portfolio

How many companies has Flagship Pioneering invested in?

Flagship Pioneering has invested in 70 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Flagship Pioneering invest in?

Flagship Pioneering's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Life Science. The firm invests across 16 different industry categories.

What is Flagship Pioneering's largest investment?

Among tracked funding rounds, Laronde received $440.0M in a Series B round. Flagship Pioneering's total known invested capital is $4.9B.

What is the average investment size for Flagship Pioneering?

Flagship Pioneering's average investment size is $73.8M across its portfolio of 70 companies.

What are Flagship Pioneering's most recent investments?

Recent Flagship Pioneering portfolio additions include Tarveda Therapeutics, Mirai Bio, Extuitive, Codiak Biosciences, Laronde. These companies were founded in 2020 or later.

Reach the founders behind these 70 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →